Global Prevalence of Multidrug Resistant Mycobacterium leprae
Author Information
Author(s): Zivarifar Hamidreza, Ahrari Forough, Karbalaei Mohsen
Primary Institution: Zahedan University of Medical Sciences
Hypothesis
This study aimed to evaluate the global prevalence of multidrug-resistant M. leprae and its implications.
Conclusion
The increasing prevalence of MDR M. leprae globally requires urgent and strategic interventions to prevent further spread.
Supporting Evidence
- The combined prevalence of drug-resistant M. leprae was approximately 11.7%.
- The global rate for MDR M. leprae was measured at 2.2%.
- Factors such as bacterial density and the lepromatous phase were associated with elevated DR M. leprae risk.
- Publication bias was assessed and found to have minimal impact on results.
Takeaway
This study found that a lot of leprosy cases are caused by drug-resistant germs, which means the usual medicines might not work well anymore.
Methodology
A systematic review and meta-analysis were conducted using PRISMA guidelines, analyzing data from human clinical trials on MDR M. leprae.
Potential Biases
Publication bias was assessed and found to have minimal impact on results.
Limitations
Low population size, persistent heterogeneity, and potential publication bias.
Participant Demographics
The studies included data from various regions, with a total of 4,454 leprosy patients categorized into new cases, monotherapy patients, MDT regimen patients, and relapse cases.
Statistical Information
P-Value
0.01
Confidence Interval
95% CI: 1.2–3.9
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website